DC Chemicals · Product datasheet

Roxadustat(FG-4592) — Datasheet

CAT. NO. DC5193

Product page and current package options

ParameterValue
Chemical NameRoxadustat
CAS No.808118-40-3
SynonymsGlycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-;FG-4592;N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine;2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid;FG4592;Roxadustat;Roxadustat (FG-4592);(((4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic acid;2-(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBOXAMIDO)ACETIC ACID;Glycine,N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]
FormulaC19H16N2O5
M.Wt352.35
SMILESO=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Roxadustat (FG-4592) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor developed for the treatment of anemia.

In Vitro

Roxadustat significantly increases accumulation of HIF-1α and BNIP3, resultes in reduced TUNEL-positive photoreceptors 3 days after RD and an increased thickness of the outer nuclear layer 7 days after RD in the TUNEL-positive cells[1]. Roxadustat increases differentiation of adipose-derived mesenchymal stem cells (ADMSCs) under both hypoxia and normoxia[2].

In Vivo

Roxadustat (25 mg/kg) enhances mitophagy and attenuates retinal histopathologic damage in the photoreceptor layer after RD in an RD animal model[1].

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation